Diagnostics Deal Trends 2025 – Part 1 Major players turn their M&A sights to platforms and technologies with broad application to drive growth.
Diagnostics M&A activity in 2025 accelerated, surpassing the prior year in both count and strategic significance. The number of M&A and asset purchase deals exceeded 150 globally, strongly surpassing 2024’s volume, at ~50 deals.
u003c!u002du002d wp:paragraph u002du002du003enu003cpu003e06/11/25u0026nbsp;|u0026nbsp;PharmaVentures Podcastsu003c/pu003enu003c!u002du002d /wp:paragraph u002du002du003ennu003c!u002du002d wp:paragraph u002du002du003enu003cpu003eAdrian Dawkes talks to PharmaVentures' Founder and CEO, Dr Fintan Walton, about the importance of strategy and preparation in today's deal making space. In the competitive, fast-paced environment of deal making within the life sciences industry, if you fail to prepare, then you must prepare to fail. Tune in to help assemble your strategy for success.u003c/pu003enu003c!u002du002d /wp:paragraph u002du002du003ennu003c!u002du002d wp:paragraph u002du002du003enu003cpu003eListen here:u003c/pu003enu003c!u002du002d /wp:paragraph u002du002du003ennu003c!u002du002d wp:embed {u0022urlu0022:u0022https://mcdn.podbean.com/mf/web/rq2d6xsr9tjvjuf7/How_strategy_and_communication_expedite_deal_outcomes8e0r6.mp3u0022,u0022typeu0022:u0022richu0022,u0022providerNameSlugu0022:u0022embed-handleru0022} u002du002du003enu003cfigure class=u0022wp-block-embed is-type-rich is-provider-embed-handler wp-block-embed-embed-handleru0022u003eu003cdiv class=u0022wp-block-embed__wrapperu0022u003enhttps://mcdn.podbean.com/mf/web/rq2d6xsr9tjvjuf7/How_strategy_and_communication_expedite_deal_outcomes8e0r6.mp3nu003c/divu003eu003c/figureu003enu003c!u002du002d /wp:embed u002du002du003ennu003c!u002du002d wp:heading {u0022levelu0022:3} u002du002du003enu003ch3 class=u0022wp-block-headingu0022u003eAbout the Presenter:u003c/h3u003enu003c!u002du002d /wp:heading u002du002du003ennu003c!u002du002d wp:paragraph u002du002du003enu003cpu003eu003cstrongu003eAdrian Dawkesu003c/strongu003e is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and Mu0026amp;A mandates.u003c/pu003enu003c!u002du002d /wp:paragraph u002du002du003ennu003c!u002du002d wp:paragraph u002du002du003enu003cpu003eDuring his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.u003c/pu003enu003c!u002du002d /wp:paragraph u002du002du003ennu003c!u002du002d wp:heading {u0022levelu0022:3} u002du002du003enu003ch3 class=u0022wp-block-headingu0022u003eAbout the Interviewees:u003c/h3u003enu003c!u002du002d /wp:heading u002du002du003ennu003c!u002du002d wp:paragraph u002du002du003enu003cpu003eu003cstrongu003eFintan Waltonu003c/strongu003eu0026nbsp;is the Founder and CEO of PharmaVentures. He has over 30 years’ experience helping clients achieve success in deal making.u003c/pu003enu003c!u002du002d /wp:paragraph u002du002du003ennu003c!u002du002d wp:paragraph u002du002du003enu003cpu003eOver a period of three decades, he has built PharmaVentures into a global player in supporting transactions for blue chip corporations and emerging innovator corporations. In that time, the firm has delivered more than 1,000 transaction related assignments for companies in 38 countries.u003c/pu003enu003c!u002du002d /wp:paragraph u002du002du003e
Join Adrian Dawkes, Managing Director at PharmaVentures, for this podcast episode exploring how the pharmaceutical manufacturing sector is evolving in response to shifting global pressures. Our experts, Ross Jenkins and Dr Gurdas Singh, unpack the critical changes shaping the industry.
Listen here:
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
About the Interviewees:
Ross Jenkins joined PharmaVentures as a Business Analyst and has since been promoted to Director, with previous experience in diagnostic start-ups and commercialisation.
Prior to joining PharmaVentures, Ross worked at a multiplex immune-diagnostic start-up in New Zealand focused on both human and animal health. During this time he was involved across all areas of the business from communications, manufacturing, quality/regulatory affairs, and market analysis. Ross holds a BSC(Hons) in Biotechnology and, a PGDip and Masters in Bioscience Enterprise from the University of Auckland.
Dr Gurdas Singh advises on both buy-side and sell-side transactions globally. He specialises in guiding companies to optimise their positioning for partnerships and M&A opportunities across diagnostics, pharmaceutical manufacturing, and healthcare services.
Gurdas holds a Master’s of Research from The University of Oxford, securing multiple research grants and having authored over 20 publications. He also earned a Bachelor’s of Medicine and Surgery (MBBS) and a Bachelor’s of Science in Medical Sciences from King’s College London.
In this podcast, PharmaVentures explores the recent changes in the landscape of Drug Pricing. This episode delves into the evolving differences between Europe and the US and how it has an impact on both. It also assesses the how Direct-to-Patient strategies, now being deployed by pharmaceutical companies in the US, can change the cost to the patient.
Listen here:
About the Presenter:
Adrian Dawkes is a Managing Director at PharmaVentures and has been with the company since 2007. Adrian has led multiple consultancy, licensing and M&A mandates.
During his professional career, Adrian has significant multi-discipline expertise spanning research and development through to sales, marketing and business development. Adrian has over 30 years' experience in the pharmaceutical, biotechnology and consultancy services sectors. Adrian holds a BSc in Biochemistry and a PhD in Immunochemistry.
About the Interviewee:
Samara Ferguson is Vice President at PharmaVentures, leading its Pricing and Market Access division, supporting companies in their sell-side, buy-side, and licensing due diligence and deal-making.
For over 20 years, Samara has held multiple roles in the pharmaceutical industry, giving her a unique insight and experience in market access, health economics and outcomes research. Samara's consultancy experience also brings many years of insight across numerous therapy areas, where she rigorously pressure-tested market access and price potential, developed market access strategies, evidence generation plans, and bespoke real-world studies. Samara holds a MSc in Health Economics and Health Policy from the University of Birmingham.
H1 2025: Acceleration, Integration, and the Shift from Innovation to Infrastructure
H1 2025 saw sustained Dx deal activity, highlighting sector resilience despite macroeconomic headwinds. We identified a total deal volume of 174 across Q1 and Q2, which was stable year-over-year (vs. 171 in H1 2024), but deal composition signalled a strategic shift.
